HOWL NASDAQ
Werewolf Therapeutics, Inc.
1W: -3.3%
1M: -7.0%
3M: +190.0%
YTD: +43.9%
1Y: -52.4%
3Y: -58.2%
5Y: -94.8%
$0.93
+0.05 (+5.29%)
Weekly Expected Move ±6.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (25)
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $4.00
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus Price Target from Analysts
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Werewolf Therapeutics GAAP EPS of -$0.28 beats by $0.01
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Thursday's After-Market Session
Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $3.75
Earnings Scheduled For March 27, 2026
Werewolf Therapeutics GAAP EPS of -$0.20 beats by $0.14
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus PT from Analysts
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 24,962 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 18,568 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know